Nanopath Secures $10M to Develop POC Diagnostics for Women’s Health
Nanopath will develop & commercialize a biosensing platform that aims to transform how women’s pelvic & gynecologic infections are diagnosed.
Read MorePosted by Andy Lundin | Aug 16, 2022 | Company News, Womens Health |
Nanopath will develop & commercialize a biosensing platform that aims to transform how women’s pelvic & gynecologic infections are diagnosed.
Read MorePosted by Andy Lundin | Aug 16, 2022 | Covid 19, Rapid Assays |
Researchers have created an easy-to-use diagnostic test for COVID infection that is more sensitive than commonly used at-home antigen tests.
Read MorePosted by Chris Wolski | Aug 12, 2022 | Clinical Chemistry Analyzers |
The July 2022 Tech Guide that appears in Clinical Lab Products (CLP) features a wide-range of products from top laboratory providers.
Read MorePosted by Andy Lundin | Aug 8, 2022 | Covid 19, Point-of-Care |
A new POC diagnostic device can simultaneously detect the presence of both SARS-CoV-2 RNA & antibodies against the virus in saliva.
Read MorePosted by Andy Lundin | Aug 2, 2022 | Covid 19 |
North American Diagnostics is recalling oral-based SARS-CoV-2 rapid tests that were distributed without authorization from the U.S. FDA.
Read More